Acute hemolytic transfusion reactions (AHTRs) are a serious and potentially life-threatening complication of blood transfusions. AHTRs occur when a person receives a unit of incompatible blood and the recipient’s immune system responds by attacking and destroying the donor’s red blood cells. It is estimated that AHTRs occur in 0.2-2.0% of all transfusions. The clinical presentation of AHTRs can vary greatly and can range from mild symptoms to severe, life-threatening reactions. In this article, we will explore the causes and treatments of AHTRs in order to better understand how to prevent and manage them.
AHTRs are a type of transfusion reaction that occurs when a person receives a unit of incompatible blood. This occurs when the recipient’s immune system recognizes the donor’s red blood cells as foreign and attacks them, leading to the destruction of the red blood cells. This can cause a variety of symptoms, including fever, chills, back pain, nausea, vomiting, shortness of breath, and low blood pressure. In severe cases, it can lead to shock, organ failure, and even death.
AHTRs can be caused by a variety of factors, including human error, laboratory errors, and technical errors. Human error can occur when a healthcare provider orders the wrong type of blood or fails to properly match the patient’s blood type. Laboratory errors can occur when the laboratory fails to properly identify the patient’s blood type or fails to detect an incompatibility between the donor and recipient. Technical errors can occur when the blood is not properly stored or handled prior to transfusion.
AHTRs are typically diagnosed based on the patient’s clinical presentation. A healthcare provider will typically order laboratory tests to confirm the diagnosis and to determine the underlying cause. These tests may include a complete blood count, a type and screen, and a crossmatch.
The treatment of AHTRs depends on the severity of the reaction. Mild reactions can usually be managed with supportive care, such as hydration, analgesia, and antipyretics. Severe reactions require more aggressive intervention, such as the administration of IV fluids, oxygen, and medications to stabilize the patient. In some cases, a blood transfusion may be necessary to replace the destroyed red blood cells.
The best way to prevent AHTRs is to ensure that the blood is properly matched prior to transfusion. This includes confirming the patient’s blood type and performing a crossmatch to make sure that the donor and recipient are compatible. Additionally, healthcare providers should be aware of the potential for human, laboratory, and technical errors and take steps to reduce the risk of these errors occurring.
AHTRs are a serious and potentially life-threatening complication of blood transfusions. They are caused by a variety of factors, including human error, laboratory errors, and technical errors. The diagnosis and treatment of AHTRs depends on the severity of the reaction, and prevention is key to avoiding these reactions. By taking steps to properly match the donor and recipient’s blood and reduce the risk of errors, healthcare providers can help ensure that transfusions are safe and successful.
1.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
2.
Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer
3.
Taking vitamin D daily decreased cancer mortality, according to a study.
4.
Study reveals increase in late-stage breast cancer diagnoses in US
5.
Prostate cancer Q&A: Improving detection and reducing overtreatment
1.
Virtual Survivorship Platforms in Cancer Care: Transforming Post-Treatment Support and Outcomes
2.
Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment
3.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
4.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
5.
Women's Cancer Survivorship: Emerging Long-Term Health Priorities
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
3.
Expert Perspectives on Hematology
4.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
5.
Navigating the Complexities of Ph Negative ALL - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation